Patent Expiry Watch

Daily infographic: a real drug, whose patent, when it expires, and what happens to the market when it does — the kind of tracking a Portfolio Retainer does continuously, made public one drug at a time.

Sep 12, 2026

Firdapse (Amifampridine): The 2035 Generic Opportunity Window

Sep 11, 2026

Biktarvy (bictegravir): The 2036 Generic Opportunity Window

Sep 7, 2026

Tivicay (dolutegravir): The 2029 Generic Opportunity Window

Sep 3, 2026

The Enbrel Patent Thicket: A Three-Decade Monopoly (2012-2029)

Sep 3, 2026

Ibrance (palbociclib): The 2027 Generic Opportunity Window

Aug 30, 2026

The Eliquis (apixaban) Opportunity Window: A Timeline to Generic Entry

Aug 30, 2026

The Keytruda (Pembrolizumab) Opportunity Window: 2028 to 2042